trending Market Intelligence /marketintelligence/en/news-insights/trending/hWfG-vDvoUj-qITl4jwNSA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Report: BioNTech IPO could fetch up to $800M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Report: BioNTech IPO could fetch up to $800M

German biopharmaceutical company BioNTech AG has hired banks for a potential IPO that could raise up to $800 million, Reuters reported March 12, citing people familiar with the matter.

BioNTech develops individualized therapies for cancer and other diseases. The company's research platforms involve messenger Ribonucleic acid-based medicines, cell and gene therapies as well as protein therapies. The German company has partnerships with pharmaceutical giants including Roche Holding AG, Eli Lilly and Co., Pfizer Inc. and Sanofi.

Reuters reported that Bank of America and JP Morgan have been hired as global coordinators for the potential Nasdaq IPO.

The IPO could occur in the fourth quarter or early in 2020.

BioNTech, which raised about $270 million in a series A financing led by Redmile Group in January 2018, could be valued at about $4 billion, according to the report.